Overview

Update
Total Equity Funding
$87.7M in 6 Rounds from 2 Investors
Most Recent Funding
$31.5M Private Equity on December 18, 2015
Headquarters:
Boston, MA
Description:
Gelesis is a biotechnology company developing first-in-class therapeutics to safely treat obese, overweight, and diabetic patients.
Founders:
Categories:
Medical Device, Biotechnology, Diabetes
Website:
http://www.gelesis.com
Social:

Company Details

Update

Gelesis is a clinical stage biotechnology company developing first-in-class therapeutics to safely treat obese, overweight, and diabetic patients. Gelesis100, our lead product, is an orally- administered smart pill which is constructed of materials that are General Recognized as Safe (GRAS) by the Food and Drug Administration (FDA). Each Gelesis100 capsule contains thousands of hydrogel particles approximately the size of a grain of salt that expand to 100 times their dry weight. The pill is designed to act mechanically in the stomach and small intestine to increase satiety and decrease hunger, resulting in reduced caloric intake and weight loss. Gelesis was founded in 2006 in Boston, Massachusetts

Funding Rounds (6) - $87.7M

Update
DateAmount / RoundValuationLead InvestorInvestors
Dec, 2015$31.5M / Private Equity0
Mar, 2015$22M / Private Equity0
May, 2014$12M / Series E0
Jun, 2011$2.6M / Venture0
May, 2011$3.6M / Series B0
Jan, 2008$16M / Series A2

Investors (2)

Offices/Locations (2)

Update
  • Headquarters

    500 Boylston St.

    Suite 1600

    Boston, MA 02420

    USA

  • Gelesis

    500 Boylston St

    Suite 1600

    Boston, MA 02116

    USA

Images (1)

Update

Add Acquisitions

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos